Nukkleus Financials
NUKK Stock | USD 1.65 0.14 7.82% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.54 | 0.57 |
|
|
The essential information of the day-to-day investment outlook for Nukkleus includes many different criteria found on its balance sheet. An individual investor should monitor Nukkleus' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Nukkleus.
Net Income |
|
Nukkleus | Select Account or Indicator |
Nukkleus Stock Summary
Nukkleus competes with Esker SA, Dear Cashmere, BASE, CurrentC Power, and Agent Information. Nukkleus Inc., a financial technology company, focuses on providing software and technology solutions for retail foreign exchange trading industry worldwide. Nukkleus Inc. operates as a subsidiary of Global Elite Holdings Ltd. Nukkleus operates under SoftwareApplication classification in the United States and is traded on OTC Exchange. It employs 12 people.Specialization | Information Technology, Software - Application |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US67053Q1076 |
CUSIP | G1643W111 67054R104 67053Q107 |
Older Symbol | BRLI |
Location | China |
Business Address | 525 Washington Boulevard, |
Sector | Software |
Industry | Information Technology |
Benchmark | Dow Jones Industrial |
Website | www.nukk.com |
Phone | 212 791 4663 |
Currency | USD - US Dollar |
Nukkleus Key Financial Ratios
Return On Equity | -7.42 | ||||
Profit Margin | (2.53) % | ||||
Operating Margin | (7.94) % | ||||
Price To Sales | 0.45 X | ||||
Revenue | 16.22 M |
Nukkleus Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 203.0K | 3.8M | 16.7M | 18.4M | 21.1M | 22.2M | |
Other Current Liab | 5.0M | 4.6M | 2.5M | 7.2M | 8.3M | 8.7M | |
Net Debt | 158.3K | 161.0K | 1.3M | (364.0K) | (418.6K) | (397.7K) | |
Retained Earnings | (1.5M) | (1.6M) | (2.5M) | (14.3M) | (12.9M) | (12.3M) | |
Cash | 23.5K | 82.8K | 355.7K | 364.0K | 418.6K | 439.6K | |
Total Liab | 1.5M | 5.2M | 4.6M | 7.5M | 8.6M | 9.0M | |
Total Current Assets | 203.0K | 3.8M | 3.0M | 3.7M | 4.2M | 4.5M | |
Net Tangible Assets | (1.3M) | (1.4M) | (1.6M) | 2.8M | 3.2M | 3.4M | |
Net Receivables | 3.7M | 2.7M | 35K | 966.1K | 1.1M | 1.0M | |
Inventory | (172.8K) | (3.7M) | (2.6M) | 2.0M | 1.8M | 1.9M | |
Other Current Assets | 3.7M | 2.6M | 3.3M | 3.3M | 3.8M | 4.0M | |
Short Term Debt | 181.8K | 243.8K | 49.0K | 3.7M | 4.2M | 4.4M | |
Net Invested Capital | (1.3M) | (1.4M) | 12.0M | 10.9M | 12.5M | 13.2M | |
Net Working Capital | (1.0M) | (1.4M) | (1.6M) | (3.8M) | (3.4M) | (3.2M) |
Nukkleus Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Operating Income | (113.1K) | (932.4K) | (6.8M) | (3.3M) | (2.9M) | (2.8M) | |
Ebit | (113.1K) | (932.4K) | (6.8M) | (1.7M) | (1.5M) | (1.6M) | |
Ebitda | (113.1K) | (463.1K) | (9.2M) | (1.5M) | (1.3M) | (1.4M) | |
Income Before Tax | (100.6K) | (936.8K) | (11.8M) | (3.3M) | (2.9M) | (2.8M) | |
Net Income | (106.6K) | (940.7K) | (11.8M) | (3.3M) | (2.9M) | (2.8M) | |
Income Tax Expense | (34.0K) | 6.0K | 3.9K | (3.3K) | (3.8K) | (4.0K) |
Nukkleus Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (234.1K) | 59.3K | 272.8K | 1.2M | 1.4M | 1.4M | |
Free Cash Flow | 59.3K | 295.9K | 1.6M | 1.6M | 1.9M | 2.0M | |
Other Non Cash Items | 8.3K | (18.6K) | 1.5K | 5.0M | 5.8M | 6.0M | |
Net Income | (730.1K) | (100.6K) | (936.8K) | (11.8M) | (10.7M) | (10.1M) | |
End Period Cash Flow | 23.5K | 82.8K | 355.7K | 2.4M | 2.7M | 2.9M |
Nukkleus Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nukkleus's current stock value. Our valuation model uses many indicators to compare Nukkleus value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nukkleus competition to find correlations between indicators driving Nukkleus's intrinsic value. More Info.Nukkleus is rated below average in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . At this time, Nukkleus' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Nukkleus by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Nukkleus Systematic Risk
Nukkleus' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nukkleus volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Nukkleus correlated with the market. If Beta is less than 0 Nukkleus generally moves in the opposite direction as compared to the market. If Nukkleus Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nukkleus is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nukkleus is generally in the same direction as the market. If Beta > 1 Nukkleus moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Nukkleus Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Nukkleus' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Nukkleus growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Nukkleus December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Nukkleus help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Nukkleus. We use our internally-developed statistical techniques to arrive at the intrinsic value of Nukkleus based on widely used predictive technical indicators. In general, we focus on analyzing Nukkleus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Nukkleus's daily price indicators and compare them against related drivers.
Downside Deviation | 9.2 | |||
Information Ratio | (0.01) | |||
Maximum Drawdown | 54.55 | |||
Value At Risk | (14.29) | |||
Potential Upside | 16.67 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nukkleus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nukkleus. If investors know Nukkleus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nukkleus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.36) | Revenue Per Share 7.024 | Quarterly Revenue Growth (0.97) | Return On Assets (1.15) | Return On Equity (7.42) |
The market value of Nukkleus is measured differently than its book value, which is the value of Nukkleus that is recorded on the company's balance sheet. Investors also form their own opinion of Nukkleus' value that differs from its market value or its book value, called intrinsic value, which is Nukkleus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nukkleus' market value can be influenced by many factors that don't directly affect Nukkleus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nukkleus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nukkleus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nukkleus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.